Gentian Diagnostics Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Gentian Diagnostics wird ein Gewinn- und Umsatzwachstum von 63.5% bzw. 25.7% pro Jahr prognostiziert, während der Gewinn pro Aktie um 103.3% pro Jahr wachsen soll.

Wichtige Informationen

63.5%

Wachstumsrate der Gewinne

103.3%

EPS-Wachstumsrate

Medical Equipment Gewinnwachstum	19.0%
Wachstumsrate der Einnahmen	25.7%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	14 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Analyst Estimates: Here's What Brokers Think Of Gentian Diagnostics ASA (OB:GENT) After Its Annual Report

Feb 14

Recent updates

Investors Appear Satisfied With Gentian Diagnostics ASA's (OB:GENT) Prospects As Shares Rocket 33%

Jun 29

Analyst Estimates: Here's What Brokers Think Of Gentian Diagnostics ASA (OB:GENT) After Its Annual Report

Feb 14

Here's Why We're Not At All Concerned With Gentian Diagnostics' (OB:GENT) Cash Burn Situation

Oct 28

We're Not Worried About Gentian Diagnostics' (OB:GENT) Cash Burn

May 11

Can You Imagine How Gentian Diagnostics' (OB:GENT) Shareholders Feel About The 57% Share Price Increase?

Mar 20

Gewinn- und Umsatzwachstumsprognosen

OB:GENT - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (NOK Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	261	32	N/A	N/A	1
12/31/2025	201	23	21	31	1
12/31/2024	151	16	8	18	1
9/30/2024	154	2	22	31	N/A
6/30/2024	153	-2	5	13	N/A
3/31/2024	149	-6	15	21	N/A
12/31/2023	142	-11	11	15	N/A
9/30/2023	129	-5	-12	-7	N/A
6/30/2023	122	-14	-6	0	N/A
3/31/2023	120	-18	-19	-6	N/A
12/31/2022	112	-24	-29	-14	N/A
9/30/2022	106	-29	-34	-19	N/A
6/30/2022	100	-26	-43	-26	N/A
3/31/2022	99	-26	-42	-29	N/A
12/31/2021	100	-25	-40	-27	N/A
9/30/2021	99	-19	-24	-9	N/A
6/30/2021	96	-19	-27	-16	N/A
3/31/2021	84	-17	-20	-12	N/A
12/31/2020	79	-17	-19	-13	N/A
9/30/2020	72	-21	-16	-13	N/A
6/30/2020	70	-19	-16	-13	N/A
3/31/2020	62	-38	-28	-25	N/A
12/31/2019	55	-40	-26	-21	N/A
9/30/2019	44	-46	-25	-20	N/A
6/30/2019	48	-41	-22	-17	N/A
3/31/2019	47	-23	-18	-12	N/A
12/31/2018	46	-20	-17	-11	N/A
9/30/2018	51	-12	-23	-18	N/A
6/30/2018	41	-16	N/A	-19	N/A
3/31/2018	40	-14	N/A	-16	N/A
12/31/2017	35	-15	N/A	-19	N/A
9/30/2017	34	-13	N/A	-19	N/A
6/30/2017	32	-12	N/A	-18	N/A
3/31/2017	30	-13	N/A	-16	N/A
12/31/2016	31	-9	N/A	-8	N/A
12/31/2015	26	-3	N/A	-5	N/A
12/31/2014	25	-3	N/A	-2	N/A
12/31/2013	23	1	N/A	2	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: GENTDas prognostizierte Gewinnwachstum (63.5% pro Jahr) liegt über der Sparquote (2.4%).

Ertrag vs. Markt: GENTDie Erträge des Unternehmens (63.5% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Norwegian (9.5% pro Jahr).

Hohe Wachstumserträge: GENTEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: GENTDie Einnahmen des Unternehmens (25.7% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Norwegian (2.3% pro Jahr).

Hohe Wachstumseinnahmen: GENTDie Einnahmen des Unternehmens (25.7% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von GENT in 3 Jahren voraussichtlich hoch sein wird

Gentian Diagnostics Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus revenue estimates decrease by 10%, EPS upgraded

Price target increased by 24% to kr67.00

Analyst Estimates: Here's What Brokers Think Of Gentian Diagnostics ASA (OB:GENT) After Its Annual Report

Consensus estimates of losses per share improve by 70%

Consensus estimates of losses per share improve by 31%

Consensus EPS estimates fall by 12%

Recent updates

Consensus revenue estimates decrease by 10%, EPS upgraded

Third quarter 2024 earnings released: EPS: kr0.22 (vs kr0.053 loss in 3Q 2023)

Second quarter 2024 earnings released: EPS: kr0.31 (vs kr0.059 in 2Q 2023)

Price target increased by 24% to kr67.00

Investors Appear Satisfied With Gentian Diagnostics ASA's (OB:GENT) Prospects As Shares Rocket 33%

Now 20% undervalued after recent price drop

First quarter 2024 earnings released: EPS: kr0.27 (vs kr0.043 loss in 1Q 2023)

Gentian Diagnostics ASA Appoints Mr. Njaal Kind as Acting CEO

Full year 2023 earnings released: kr0.69 loss per share (vs kr1.53 loss in FY 2022)

Analyst Estimates: Here's What Brokers Think Of Gentian Diagnostics ASA (OB:GENT) After Its Annual Report

Full year 2023 earnings released: kr0.67 loss per share (vs kr1.53 loss in FY 2022)

Gentian Diagnostics Asa Announces Resignation of Frank Frantzen from the Board of Directors

Gentian Diagnostics ASA to Report Q4, 2023 Results on Feb 09, 2024

Consensus estimates of losses per share improve by 70%

New major risk - Revenue and earnings growth

Third quarter 2023 earnings released

CFO & COO recently bought kr217k worth of stock

First quarter 2023 earnings released

Consensus estimates of losses per share improve by 31%

Full year 2022 earnings: EPS exceeds analyst expectations

Gentian Diagnostics Asa Announces New Study Addresses the Use of Plasma Calprotectin in Sepsis Management

Consensus EPS estimates fall by 12%

Price target decreased by 43% to kr52.00

Gentian Diagnostics ASA Announces Executive Changes, Effective from 1 January 2023

Gentian Diagnostics ASA to Report Q4, 2022 Results on Feb 16, 2023

Gentian Diagnostics ASA, Annual General Meeting, May 04, 2023

Gentian Diagnostics ASA Receives Patent for NT-proBNP in the U.S

No independent directors

Consensus forecasts updated

Third quarter 2022 earnings: Revenues exceed analyst expectations

Here's Why We're Not At All Concerned With Gentian Diagnostics' (OB:GENT) Cash Burn Situation

Consensus forecasts updated

Director recently bought kr96k worth of stock

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Gentian Diagnostics ASA Announces Executive Appointments

We're Not Worried About Gentian Diagnostics' (OB:GENT) Cash Burn

First quarter 2022 earnings: Revenues miss analyst expectations

No independent directors

Gentian Diagnostics Asa Announce the Release of the Novel Ce Marked Sars-Cov-2 Total Antibody Immunoassay

Director recently bought kr203k worth of stock

Consensus forecasts updated

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Gentian Diagnostics AS Completes Development of SARS Cov-2 Antibody Assay

Third quarter 2021 earnings released

Price target increased to kr104

Second quarter 2021 earnings released: kr0.23 loss per share (vs kr0.092 loss in 2Q 2020)

First quarter 2021 earnings released

Can You Imagine How Gentian Diagnostics' (OB:GENT) Shareholders Feel About The 57% Share Price Increase?

What Percentage Of Gentian Diagnostics AS (OB:GENT) Shares Do Insiders Own?

Gentian Diagnostics as Announces Publication of NT-ProBNP Patent Application

Full year 2020 earnings released: kr1.13 loss per share (vs kr2.59 loss in FY 2019)

Have Insiders Been Selling Gentian Diagnostics AS (OB:GENT) Shares?

New 90-day low: kr52.50

New 90-day low: kr56.00

Gentian Diagnostics AS (OB:GENT): When Will It Breakeven?

Gentian Diagnostics AS Announces New Study Results Confirm the Value of Calprotectin in Management of COVID-19 Patients

New 90-day low: kr60.50

Third quarter earnings released

Insider recently sold kr3.0m worth of stock

Earnings released

New 90-day high - kr64.00

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken